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ABSTRACT
Background There is a high prevalence of COVID-19 in university-age students, who are returning to campuses. There is little evidence
regarding the feasibility of universal, asymptomatic testing to help control outbreaks in this population. This study aimed to pilot mass
COVID-19 testing on a university research park, to assess the feasibility and acceptability of scaling up testing to all staff and students.
Methods This was a cross-sectional feasibility study on a university research park in the East of England. All staff and students (5625) were
eligible to participate. All participants were offered four PCR swabs, which they self-administered over two weeks. Outcome measures included
uptake, drop-out rate, positivity rates, participant acceptability measures, laboratory processing measures, data collection and management
measures.
Results 798 (76%) of 1053 who registered provided at least one swab; 687 (86%) provided all four; 792 (99%) of 798 who submitted at least
one swab had all negative results and 6 participants had one inconclusive result. There were no positive results. 458 (57%) of 798 participants
responded to a post-testing survey, demonstrating a mean acceptability score of 4.51/5, with five being the most positive.
Conclusions Repeated self-testing for COVID-19 using PCR is feasible and acceptable to a university population.
D
ow
nloaded from
 https://academ
ic.oup.com
/jpubhealth/advance-article/doi/10.1093/pubm
ed/fdaa194/5942928 by U
niversity of East Anglia user on 06 N
ovem
ber 2020
2 JOURNAL OF PUBLIC HEALTH
Introduction
Universities are considering methods of dealing with the
transmission of COVID-19 when students return to campus.
Student populations are likely to have a higher than aver-
age prevalence of infection1, and in particular, a high rate
of asymptomatic infection.2 This population is also highly
mobile and more likely to have a large number of social con-
tacts.3 It remains unclear how an outbreak might evolve on a
university campus, but modelling studies suggest that students
are highly interconnected, indicating significant potential for
infectious disease transmission.4,5 Colleges in the UK and
USA have already reported outbreaks among the student
population, necessitating closure in some cases.6 The UK
government is exploring community-wide testing for asymp-
tomatic COVID-19 infection as a potential health protection
tool, to enable outbreaks to be identified and controlled early.7
A SAGE consensus statement has suggested that such a
strategy might be useful in ‘well-defined higher risk settings’,
such as universities.8 This method is largely untested within a
university setting, however. This pilot study was based in the
Norwich Research Park (NRP), which includes the University
of East Anglia (UEA) and a range of business and research
institutions. The study offered four COVID-19 polymerase
chain reaction (PCR) swabs to all staff and students on the
site over a two-week period. The aim of the study was to pilot
participant guidance materials, logistics, laboratory and data
processes and the user-facing web application. It also aimed
to establish costs and to assess participant acceptability.
Methods
All participants living or working on the NRP were eligible
to participate and were invited to join the study via an email
cascade to staff and students. Ethics approval (no. 2019/20–
140) was obtained from the UEA research ethics committee.
A secure web application was developed and hosted by the
School of Computing Sciences at the UEA. This involved the
design and implementation of software to facilitate partici-
pant sign-up for booking slots, email authentication and data
management protocols to host test results and participant per-
sonal data. Participants registered on the web application and
were invited to verify their email accounts and sign in using
an industry standard authentication protocol. All those who
verified their accounts were considered to have enrolled in the
study. About, 180 people participated in a pre-trial, in which
they returned two swabs. For the main study, participants were
offered four swab tests over two weeks. They collected swab
kits, self-administered the swab and returned the test in pre-
booked return slots. For the purposes of this report, the pre-
trial and main trial are considered as a single trial.
Swabs were processed in dedicated laboratory facilities at
the Earlham Institute (EI) from Monday to Friday. Copan
Liquid Amies Elution Swabs (Eswabs) were used for all par-
ticipants. Participant samples were tested for the presence of
SARS-COV-2 using a quantitative polymerase chain reaction
(qPCR) assay. Briefly, nasopharyngeal swab samples were
pre-treated with a lysis buffer (Cytiva) that disrupts human
cells and viral particles to release nucleic acid into solution.
Following inactivation, RNA was extracted using Sera-Xtracta
Virus/Pathogen Kit (Cytiva) on a liquid handling platform
(Beckman NXp). RNA extracts were amplified for detec-
tion of the target genes using a set of optimised primers
and probes (2019-nCoV CDC EUA Kit, IDT), and enzymes
(qPCRBIO Probe 1-Step Go No-ROX, PCRBioystems) in
a real-time PCR system (Quantstudio5, Thermofisher). The
assay is qualitative with results assessed based on a threshold
cycle (Ct value) to determine outcome (positive, negative,
insufficient) using a combination of Ct value for the viral
target (N1) and human internal control gene (RPP30) genes.
Positive and negative controls were included in every RNA
extraction and qPCR run for quality control. Sample data were
managed at EI using Exemplar LIMS® from Sapio Sciences.
Result data were processed from these samples using Python
3 scripts developed at EI and running on virtual infrastructure
provided by the CyVerse UK cloud. Validated participant
results were then sent to the information systems at UEA
using secure web services.
Negative or inconclusive results were posted on partici-
pants’ online accounts, with additional encoding and encryp-
tion protocols deployed to maintain data security. A protocol
for managing positive results was developed, including noti-
fying participants and NHS Track and Trace by telephone,
and advising participants to share their results with their GP.
After the completion of the feasibility project, participants
who had returned at least one swab were emailed a link to
complete a short online participant feedback questionnaire,
including questions on demographics and their experience of
the project. Groups were compared with Chi-squared tests,
and free text responses were analysed by extraction of key
themes. Participant demographics were summarised in a table,
and Chi-squared tests used to compare those who enrolled but
did not participate in the study, and those who did participate.
Resource use was summarised in a table and the flow of
participants and swabs through the study summarised in a
flow diagram.
Results
Results are summarised in Figs 1 and 2 and Tables 1 and 2.
In total, 180 people participated in the pre-trial and another
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Fig. 1 Flow of participants through the study and main results.
873 in the main trial (Table 1). In total, 458 participated in the
post-study survey (Fig. 2).
About, 19% of the eligible population enrolled in the
study and 24% of these dropped out of the study prior to
returning any samples (Fig. 1); 86% (687/798) of participants
who received at least one result returned all four swabs and 6
participants received one inconclusive result. All other results
were negative. All participants received at least one negative
swab. Participants could choose to return their swabs on foot
or by car: pedestrian access sites were favoured over vehicle
access sites. There was no lag between the results upload and
participants receiving their result notification via email. The
post-trial survey found that the overall acceptability rating was
4.5/5 stars (with 5 being the most positive) and 97% of partic-
ipants would take up repeat testing if available. Self-swabbing
received the lowest score for participant acceptability
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Fig. 2 Participant responses.
Table 1 Participant characteristics
Total n = 1053a Percentageb
Sex
Female 579 55.0%
Male 436 41.4%
Non-binary 4 0.4%
Prefer not to say 34 3.2%
Age band (years)
18–24 120 11.4%
25–34 328 31.1%
35–44 258 24.5%
45–54 201 19.1%
55–64 118 11.2%
65+ 28 2.7%
Ethnicity
Asian 60 5.7%
Black 2 0.2%
Mixed 31 2.9%
Other 22 2.1%
Prefer not to say 49 4.7%
White 889 84.4%
aTotal participants who registered for the study and validated their
account.
bThere was no significant demographic difference between those
enrolled but did not participate and those who did participate.
(71% agreed or strongly agreed that taking the swabs was
easy to do). About, 81% of responders to the post-trial survey
were staff and 16% were students.
Guidance documents
An analysis of guidance documents provided for participants,
including an instruction leaflet, standard emails and website
text found an average Flesch reading ease score of 60.1. This
indicates that material should be comprehensible to a person
aged 13–15 years. The instruction leaflet for participants
undertaking swabbing had a score of 74, which indicates
greater readability. The text for participants opening an online
account had a score of 46.8, which indicates that the reader
requires a university education to understand the text.
Participant acceptability
Participant acceptability was assessed in two rounds: first
by inviting email comments during the testing process and
second by a formal survey. Key themes emerging from par-
ticipant emails included eligibility and uncertainty about the
logistical processes. There were very few emails regarding the
process of self-swabbing.
About, 458 participants (57%) responded to the survey,
which included 11 questions about the acceptability of the
process, with responders choosing their response to each
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Table 2 Resources
Laboratory staff time [excluding planning
and reporting]
1200 hours
Total laboratory staff salary costs [excluding
planning and reporting]
£19 385
Average sample processing time 35.5 hours
Weekday average sample processing time 25.5 hours
Administrative staff time estimate 500 hours
Laboratory consumables cost estimate per
test kit
£3.61
Total number of swabs supplied to
participants
3360
Incurred costa £75 906
Estimated in-kind contributionsb £89 612
aThis figure represents the spend on services and equipment. The
feasibility study inevitably incurred a high unit cost, and for example
tripling the test numbers would have a negligible effect on cost.
bThis figure represents the costs absorbed by the existing service.
question on a 5-point scale from ‘strongly agree’ (scored as
5) to ‘strongly disagree’ (scored as 1) (Fig. 2). Responders
were generally positive about their experience of the project,
and the overall mean response score was 4.51 stars out of 5
(with 5 being the most positive). About, 89% of those who
responded to the survey returned all four swabs. About, 34%
of responders were working or studying on site, with the rest
working either partly or exclusively from home, and 77.5% of
survey responders lived 5 miles or less from the NRP. Respon-
ders were not significantly more likely than all 798 participants
to have returned all four swabs (89 and 86% respectively,
P = 0.46). There were no statistically significant differences
between those who provided all four swabs (n = 409), and
those who provided fewer than 4 (n = 49) in demographics
or any answers, including the mean response score (4.54 and
4.50 stars out of 5, respectively, P = 0.83). In total, 43 of
the 49 responders who provided fewer than four swabs gave
a reason: 21 (48%) were away during part of the study, and
another 8 (19%) forgot or were unexpectedly busy with other
commitments.
In total, 266 responders (59%) answered the free text
questions (‘Is there any feedback you would like to share
about any aspect of your participation in the project’? and
‘Is there a reason why you were unable to take any self-swab
samples’?). Responses were generally positive and included
requests for ongoing testing, feedback on results of the study
and praise for organisation and response to enquiries. Respon-
ders recommended clearer communication on the variability
of time to receive results, as some interpreted a longer wait
as being suggestive of a positive result. They also provided
useful feedback on the usability of the web application, partic-
ularly the sign-up process: they requested a simpler approach,
and recommended changes to the presentation of results to
reduce anxiety. Responders also requested clearer instructions
regarding packing samples.
Discussion
Main findings of this study
In total, 827 participants took and delivered their swabs over
a two-week period. The relatively low uptake can be explained
by the timing of the study during the summer break, the
absence of staff from campus due to working-from-home
policies and a short run-up to the study. Nearly, a quarter
of participants dropped out of the study prior to returning
any samples. The reasons for this were unclear from the
evaluation; however, there was no significant demographic
difference between those who enrolled in the study but did
not participate, and those who did participate.
The sex distribution of the eligible population was not
available; it is therefore not possible to determine whether the
sample population (55% women) was reflective of the eligible
population. The ethnic distribution of the study population
was broadly reflective of the population of Norwich: 10.9%
of participants were of Asian, black, mixed or ‘other’ ethnic-
ity, compared to 9.1% for Norwich.9
The study did not identify any false positives, despite this
being considered a risk of universal testing.10 An analysis of
guidance documents and participant emails indicates a need
for clearer information tailored to the eligible population. The
participant questionnaire revealed a high level of participant
engagement and acceptability. Combined with the low drop-
out rate after taking the first swab (86% of participants who
returned at least one swab returned all four), this suggests
that participants found self-swabbing and the collection and
delivery of samples generally acceptable.
The laboratory and web application processed 3046 swabs
during the study. Laboratory processes were efficient, with
an average processing time of just over 24 hours during the
week. The reagent cost per test of £3.61 was based on a
batch size of 6000 tests, which were ordered quickly from
outside the UK, and we would expect lower costs per test in a
larger initiative. The secure web application was hosted by the
School of Computing Sciences at minimum cost. Similarly,
the computing infrastructure at EI was provided in kind by
CyVerse UK at minimal cost to the project.
What is already known on this topic
The evidence base for use of asymptomatic testing for
COVID-19 as an infection control measure remains limited.
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Universal, repeat testing has been advocated, however, as
a means of avoiding lockdown.11 Universities across the
world are now considering universal testing despite the
pitfalls of this strategy, which include false-positive and false-
negative tests, the difficulty of defining an active infection
and significant cost.10,12 UK universities and colleges in
the USA have already reported outbreaks of COVID-19.12
The potential for COVID-19 transmission in universities is
significant, particularly shortly after the beginning of term
when students return to campus.4,5 Models demonstrate that
universal testing may have a significant impact on control
of the virus, depending on the ability of the setting to
implement other control methods.13 There is, however, no
published study assessing the feasibility or acceptability of a
universal programme for COVID-19 testing on a university
campus.
What this study adds
This pilot study indicates that universal testing on a university
campus is both feasible and acceptable to the population. A
strength of this study is that it trialled the feasibility of repeat
testing for COVID-19 in a relatively large, asymptomatic
population within a research park and university campus.
Participants included both staff and students, and the findings
can be applied both to a larger study on the same site and to
other university contexts. There was a high level of participant
engagement with the study. This study has demonstrated that
clear, consistent communications and an intuitive web appli-
cation are necessary for helping participants to understand the
need for testing and the process of undertaking and returning
the test.
Both universal testing and the current UK national public
health strategy of testing symptomatic people via a local test-
ing site have strengths and weaknesses. The current national
strategy of symptomatic testing is adequate when there are
few cases in the community, and is cheaper in the short term,
but risks allowing undetected spread of COVID-19 when
cases start to rise in a community, particularly when results
take more than 24 hours to be reported. The main potential
problem with universal testing is that it may generate false
positives, and therefore unnecessary contact tracing and iso-
lation. It is also more expensive in the short term. There were
no false positives out of 3046 tests in this study. The main
advantage of universal testing is that it can identify infectious
asymptomatic cases and isolate them before they can infect
others in the community. This is a major benefit on a campus
university with large numbers of students in a community
where isolation and social spacing may be challenging to
maintain, and where a major outbreak would have serious
consequences for students’ education, the university and the
local community.
Limitations of this study
Limitations of the study include the relatively low uptake and
the low prevalence of COVID-19 in this population, which
meant that processes for managing positive results could not
be tested. At the time of the study, community prevalence
of COVID-19 was approximately 1 in 1700 people.15 As this
was a self-selecting cohort of university staff and students,
motivation to participate may be higher than in the general
population. The findings are generalizable to university staff
but may be less generalizable to new undergraduates. This
study used PCR swabs but acceptability of some alterna-
tive testing methods, such as saliva testing, may be even
higher.
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